Skip to main content
. 2020 Aug 5;12(13):997–1006. doi: 10.2217/imt-2020-0075

Figure 4. . Probability of patient progression-free survival and overall survival.

Figure 4. 

(A) Patient median PFS was 14.82 months (95% CI: 0–31.20 months) after ASCT and CAR T-cell sequential treatment. PFS rate at 6 months was 64.29% (95% CI: 39.18–89.40%). (B) Median OS was not reached. OS rate at 1 year was 65.48% (95% CI: 36.00–94.96%). In both (A & B), dotted lines represent 95% CI.

ASCT: Autologous hematopoietic stem cell transplantation; CAR: Chimeric antigen receptor; OS: Overall survival; PFS: Progression-free survival.